WASHINGTON (AP) _ A government advisory committee is scrutinizing an inhaled form of insulin that is designed to help millions of people with diabetes who now rely on injections to control their blood sugar.
Chief concerns about the drug involve its long-term effects on the lungs, as well as whether it is safe and effective on people who smoke or have lung disease, according to documents released by the Food and Drug Administration.
The inhaled insulin, called Exubera, could help diabetics who are reluctant to take injections. The insulin is being developed by Pfizer, Sanofi-Aventis and Nektar Therapeutics.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee was to consider Thursday whether to recommend the drug to government regulators for approval. The FDA usually follows the recommendations of its advisory committees, but it isn't required to.
During drug trials, researchers found that inhaled insulin was generally as effective as injections in controlling blood sugar levels. However, some patients who took inhaled insulin complained of coughing and a small decrease in breathing capacity.
It is estimated that more than 18 million people in the United States have diabetes, although some do not know it. Most have Type 2, a condition linked to obesity that occurs when the body cannot effectively use the insulin it makes. Sometimes this can be treated with pills instead of injections.
Fewer than 10 percent have Type 1, a disorder in which the immune system attacks insulin-producing cells in the pancreas. This is sometimes called juvenile diabetes.
The number of people in the United States who have diabetes is believed to have tripled in the last quarter-century.
Inhaled insulin could be used to manage blood sugar levels for people with either type who need insulin injections before meals. It wouldn't replace longer-acting insulin injections people with Type 1 diabetes need to take in the morning or before bed, according to FDA documents.
On Friday, the advisory committee will consider another Type 2 diabetes treatment, muraglitazar, developed by Bristol-Myers Squibb. Tablets would be sold under the trade Pargluva and would control blood sugar levels.